Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Probiotic Formulation to Prevent or Mitigate Antipsychotic Induced Metabolic Side-effects - A Multi-centre Randomized Placebo-controlled Double-blind Trial

NCT07606014 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT07606014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07606014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Probiotic Formulation to Prevent or Mitigate Antipsychotic Induced Metabolic Side-effects - A Multi-centre Randomized Placebo-controlled Double-blind Trial
Lead sponsor
University Medical Center Groningen
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 1, 2026
Completion date
May 1, 2029
Enrollment
112 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

patients using olanzapine, quetiapine, risperidone or clozapine